Cristiana Sessa, M.D., of the Oncology Institute of Southern Switzerland, discusses the evolution of how PARP inhibitors are used to treat ovarian cancer.
Cristiana Sessa, M.D.
Advertisement
Articles by Cristiana Sessa, M.D.
Advertisement
Latest Updated Articles
The Evolution of PARP Inhibitors in Ovarian CancerPublished: January 16th 2018 | Updated:
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Enoby and Xtrenbo Biosimilars for Bone Health and Cancer Care
2
New Strategy May Prevent Breast Cancer Relapse
3
All FDA Oncology Approvals From September 2025
4
Understanding the Evolving Role of a Pathologist in Lung Cancer Care
5
